Summary DiaMedica Therapeutics Inc (DiaMedica), formerly DiaMedica Inc is a biopharmaceutical company that concentrates on recombinant proteins and monoclonal antibodies. The company’s product portfolio includes DM199 acute ischemic stroke, DM199 acute kidney injury, and DM199 type 2 diabetes. Its DM-199 is a human recombinant protein that treats diabetes type 1 and type 2, and associated complications including diabetic kidney disease and Alport Syndrome. DiaMedica’s DM199 acute kidney injury is a protein that is designed to treat chronic kidney disease and end-stage renal disease. The company discovers and develops novel therapies for kidney dysfunction and metabolic disorders. It provides products for strokes, orphan diseases and vascular diseases. DiaMedica is headquartered in Minneapolis, Minnesota, the US. DiaMedica Therapeutics Inc (DMA) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report... Research Beam Model: Research Beam Product ID: 2637622 250 USD New
DiaMedica Therapeutics Inc (DMA) - Medical Equipment - Deals and Alliances Profile
 
 

DiaMedica Therapeutics Inc (DMA) - Medical Equipment - Deals and Alliances Profile

  • Category : Medical Devices
  • Published On : October   2017
  • Pages : 21
  • Publisher : GlobalData
 
 
 
Summary

DiaMedica Therapeutics Inc (DiaMedica), formerly DiaMedica Inc is a biopharmaceutical company that concentrates on recombinant proteins and monoclonal antibodies. The company’s product portfolio includes DM199 acute ischemic stroke, DM199 acute kidney injury, and DM199 type 2 diabetes. Its DM-199 is a human recombinant protein that treats diabetes type 1 and type 2, and associated complications including diabetic kidney disease and Alport Syndrome. DiaMedica’s DM199 acute kidney injury is a protein that is designed to treat chronic kidney disease and end-stage renal disease. The company discovers and develops novel therapies for kidney dysfunction and metabolic disorders. It provides products for strokes, orphan diseases and vascular diseases. DiaMedica is headquartered in Minneapolis, Minnesota, the US.

DiaMedica Therapeutics Inc (DMA) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
DiaMedica Therapeutics Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
DiaMedica Therapeutics Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 6
DiaMedica Therapeutics Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
DiaMedica Therapeutics Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
DiaMedica Therapeutics Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
DiaMedica Therapeutics Inc, Medical Equipment, Deal Details 10
Equity Offering 10
DiaMedica Therapeutics Raises USD2 Million in Private Placement of Units 10
DiaMedica Raises USD0.3 Million in Private Placement of Shares 11
DiaMedica Raises USD0.6 Million in Private Placement of Shares 12
DiaMedica Therapeutics Inc - Key Competitors 13
DiaMedica Therapeutics Inc - Key Employees 14
DiaMedica Therapeutics Inc - Locations And Subsidiaries 15
Head Office 15
Recent Developments 16
Financial Announcements 16
Nov 28, 2016: DiaMedica Announces Results of Annual General and Special Meeting of Shareholders 16
Corporate Communications 17
Oct 12, 2016: DiaMedica Establishes Neurological Scientific Advisory Board With Several Distinguished Experts 17
May 09, 2016: DiaMedica Appoints Dr. Todd Verdoorn as Chief Scientific Officer 18
Jan 20, 2016: DiaMedica Appoints Dr. Todd Verdoorn as Vice President of Neuroscience 19
Legal and Regulatory 20
Dec 23, 2016: DiaMedica Announces Name Change to DiaMedica Therapeutics 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21
List of Tables
DiaMedica Therapeutics Inc, Medical Equipment, Key Facts, 2016 2
DiaMedica Therapeutics Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
DiaMedica Therapeutics Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
DiaMedica Therapeutics Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 6
DiaMedica Therapeutics Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
DiaMedica Therapeutics Inc, Deals By Market, 2011 to YTD 2017 8
DiaMedica Therapeutics Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
DiaMedica Therapeutics Raises USD2 Million in Private Placement of Units 10
DiaMedica Raises USD0.3 Million in Private Placement of Shares 11
DiaMedica Raises USD0.6 Million in Private Placement of Shares 12
DiaMedica Therapeutics Inc, Key Competitors 13
DiaMedica Therapeutics Inc, Key Employees 14
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter